{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:53:27Z","timestamp":1791302007659,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Public Health Research Foundation"},{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corp.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00198-021-05996-2","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T22:02:16Z","timestamp":1621288936000},"page":"2301-2311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8053-1095","authenticated-orcid":false,"given":"H.","family":"Hagino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6817-5235","authenticated-orcid":false,"given":"S.","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Sone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0955-2747","authenticated-orcid":false,"given":"S.","family":"Soen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7660-5562","authenticated-orcid":false,"given":"S.","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"key":"5996_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3\u201344","journal-title":"Osteoporos Int"},{"key":"5996_CR2","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 104:1595\u20131622","journal-title":"J Clin Endocrinol Metab"},{"key":"5996_CR3","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1210\/jc.2011-3060","volume":"97","author":"MH Murad","year":"2012","unstructured":"Murad MH, Drake MT, Mullan RJ et al (2012) Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 97:1871\u20131880","journal-title":"J Clin Endocrinol Metab"},{"key":"5996_CR4","unstructured":"Eli Lilly and Company (2012) FORTEO highlights of prescribing information. https:\/\/pi.lilly.com\/us\/forteo-pi.pdf. Accessed 26 January 2021"},{"key":"5996_CR5","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1359\/jbmr.081215","volume":"24","author":"R Eastell","year":"2009","unstructured":"Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Brixen K, Gomes JM, Obermayer-Pietsch B, Avramidis A, Sigurdsson G, Gl\u00fcer CC (2009) Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 24:726\u2013736","journal-title":"J Bone Miner Res"},{"key":"5996_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00198-007-0485-y","volume":"19","author":"S Adami","year":"2008","unstructured":"Adami S, San Martin J, Mu\u00f1oz-Torres M, Econs MJ, Xie L, Dalsky GP, McClung M, Felsenberg D, Brown JP, Brandi ML, Sipos A (2008) Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int 19:87\u201394","journal-title":"Osteoporos Int"},{"key":"5996_CR7","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1210\/en.2015-2028","volume":"157","author":"T Yamamoto","year":"2016","unstructured":"Yamamoto T, Hasegawa T, Sasaki M, Hongo H, Tsuboi K, Shimizu T, Ota M, Haraguchi M, Takahata M, Oda K, Luiz de Freitas PH, Takakura A, Takao-Kawabata R, Isogai Y, Amizuka N (2016) Frequency of teriparatide administration affects the histological pattern of bone formation in young adult male mice. Endocrinology 157:2604\u20132620","journal-title":"Endocrinology"},{"key":"5996_CR8","doi-asserted-by":"publisher","unstructured":"Takakura A, Lee J-W, Hirano K, Isogai Y, Ishizuya T, Takao-Kawabata R, Iimura T (2017) Administration frequency as well as dosage of PTH are associated with development of cortical porosity in ovariectomized rats. Bone Res 5. https:\/\/doi.org\/10.1038\/boneres.2017.2","DOI":"10.1038\/boneres.2017.2"},{"key":"5996_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.bone.2017.03.042","volume":"99","author":"R Zebaze","year":"2017","unstructured":"Zebaze R, Takao-Kawabata R, Peng Y, Zadeh AG, Hirano K, Yamane H, Takakura A, Isogai Y, Ishizuya T, Seeman E (2017) Increased cortical porosity is associated with daily, not weekly, administration of equivalent doses of teriparatide. Bone 99:80\u201384","journal-title":"Bone"},{"key":"5996_CR10","doi-asserted-by":"publisher","first-page":"e0175329","DOI":"10.1371\/journal.pone.0175329","volume":"12","author":"H Yamane","year":"2017","unstructured":"Yamane H, Takakura A, Shimadzu Y, Kodama T, Lee JW, Isogai Y, Ishizuya T, Takao-Kawabata R, Iimura T (2017) Acute development of cortical porosity and endosteal na\u00efve bone formation from the daily but not weekly short-term administration of PTH in rabbit. PLoS One 12:e0175329. https:\/\/doi.org\/10.1371\/journal.pone.0175329","journal-title":"PLoS One"},{"key":"5996_CR11","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1210\/jc.2011-3479","volume":"97","author":"T Nakamura","year":"2012","unstructured":"Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M (2012) Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097\u20133106","journal-title":"J Clin Endocrinol Metab"},{"key":"5996_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1185\/03007995.2012.761956","volume":"29","author":"T Sugimoto","year":"2013","unstructured":"Sugimoto T, Shiraki M, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Kuroda T, Nakamura T (2013) Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial. Curr Med Res Opin 29:195\u2013203","journal-title":"Curr Med Res Opin"},{"key":"5996_CR13","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1056\/NEJMoa050336","volume":"353","author":"DM Black","year":"2005","unstructured":"Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ (2005) One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353:555\u2013565","journal-title":"N Engl J Med"},{"key":"5996_CR14","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s00774-019-01074-0","volume":"38","author":"S Tanaka","year":"2020","unstructured":"Tanaka S, Mori S, Hagino H, Sugimoto T (2020) Design of a randomized trial of teriparatide followed by alendronate: Japanese Osteoporosis Intervention Trial-05 (JOINT-05). J Bone Miner Metab 38:412\u2013417","journal-title":"J Bone Miner Metab"},{"key":"5996_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00774-013-0447-8","volume":"31","author":"S Soen","year":"2013","unstructured":"Soen S, Fukunaga M, Sugimoto T et al (2013) Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab 31:247\u2013257","journal-title":"J Bone Miner Metab"},{"key":"5996_CR16","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137\u20131148","journal-title":"J Bone Miner Res"},{"key":"5996_CR17","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1210\/er.2001-9002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, The Osteoporosis Methodology Group, The Osteoporosis Research Advisory Group (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570\u2013578","journal-title":"Endocr Rev"},{"key":"5996_CR18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, M\u00f6ricke R, L\u00f3pez-Romero P (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391:230\u2013240","journal-title":"Lancet"},{"key":"5996_CR19","doi-asserted-by":"publisher","first-page":"115081","DOI":"10.1016\/j.bone.2019.115081","volume":"130","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Martyn-St James M, Hamilton J, Wong R, Gittoes N, Selby P, Davis S (2020) Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: a systematic review and network meta-analysis. Bone. 130:115081. https:\/\/doi.org\/10.1016\/j.bone.2019.115081","journal-title":"Bone."},{"key":"5996_CR20","unstructured":"Japan Osteoporosis Society (2015) Japanese 2015 guidelines for prevention and treatment of osteoporosis (in Japanese). http:\/\/www.josteo.com\/ja\/index.html. Accessed 26 January 2021"},{"key":"5996_CR21","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1359\/jbmr.060802","volume":"21","author":"P Chen","year":"2006","unstructured":"Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH (2006) Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 21:1785\u20131790","journal-title":"J Bone Miner Res"},{"key":"5996_CR22","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1359\/jbmr.2003.18.3.539","volume":"18","author":"JR Zanchetta","year":"2003","unstructured":"Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL (2003) Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18:539\u2013543","journal-title":"J Bone Miner Res"},{"key":"5996_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00198-012-2159-7","volume":"24","author":"M Shiraki","year":"2013","unstructured":"Shiraki M, Sugimoto T, Nakamura T (2013) Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women. Osteoporos Int 24:219\u2013226","journal-title":"Osteoporos Int"},{"key":"5996_CR24","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMra067395","volume":"357","author":"E Canalis","year":"2007","unstructured":"Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905\u2013916","journal-title":"N Engl J Med"},{"key":"5996_CR25","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s12325-017-0568-x","volume":"34","author":"T Sugimoto","year":"2017","unstructured":"Sugimoto T, Shiraki M, Fukunaga M, Hagino H, Sone T, Nakano T, Kishimoto H, Ito M, Yoshikawa H, Kishida M, Irie C, Nakamura T (2017) 24-month open-label teriparatide once-weekly efficacy research trial examining bone mineral density in subjects with primary osteoporosis and high fracture risk. Adv Ther 34:1727\u20131740","journal-title":"Adv Ther"}],"updated-by":[{"DOI":"10.1007\/s00198-021-06066-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000}}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-05996-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-021-05996-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-05996-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T10:05:54Z","timestamp":1635847554000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-021-05996-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["5996"],"URL":"https:\/\/doi.org\/10.1007\/s00198-021-05996-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00198-021-06066-3","asserted-by":"object"}]},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,17]]},"assertion":[{"value":"21 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00198-021-06066-3","URL":"https:\/\/doi.org\/10.1007\/s00198-021-06066-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H Hagino has received lecture fees or grants outside the submitted work from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Mitsubishi Tanabe Pharma Corp., Mochida Pharma Co., Ltd, Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Taisho Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd.T Sugimoto has received research grants from Asahi Kasei Pharma Corp., Astellas Pharma Inc., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer Japan Inc., and Teijin Pharma Co., Ltd., as well as consulting fees from Kissei Pharmaceutical Co., Ltd., Shimadzu Corp., and Takeda Pharmaceutical Co., Ltd.S Tanaka has received lecture fees from Astra-Zeneca, Taiho Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd.; consultation fees from DeNA Life Science Inc. and CanBus; and outsourcing fees from Satt Co., Ltd. and Asahi Kasei Pharma Corp.T Sone has received research grants from Astellas Pharma Inc., Eisai Co., Ltd., Daiichi-Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Eli Lilly Japan Co., Ltd., as well as consulting and\/or lecture fees from Asahi Kasei Pharma Corp., MSD Co., Ltd., and Daiichi-Sankyo Co., Ltd.T Nakamura has received reports personal fees and other from Asahi Pharma Corp., Teijin Pharma Ltd., Daiichi-Sankyo Pharma Co., Ltd., UCB Japan Co., Ltd., Amgen Inc., Astellas Pharma Inc., and Chugai Pharma Co., Ltd. as well as personal fees and other from Merck & Co., Inc.S Soen has received consulting fees, speaking fees, and\/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Mochida Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd.K Sasaki and S Mori declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"The protocol was approved by the certified review board of Toranomon Hospital and the central ethics committee of the Adequate Treatment of Osteoporosis research group.All procedures performed in this study were in accordance with the Clinical Trials Act of the Japanese Ministry of Health, Labour, and Welfare and with the 1964 Helsinki declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written, informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All patients provided written, informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}